Keyphrases
Pseudomonas Aeruginosa (P. aeruginosa)
100%
Healthcare Settings
100%
Baumannii
100%
Acinetobacter Infections
100%
Resistant Strains
60%
Treatment Options
40%
Multidrug-resistant Pseudomonas Aeruginosa (MDRPA)
40%
Hospitalized Patients
20%
Nosocomial Infection
20%
Antibiotics
20%
Extended-spectrum-lactamase
20%
Gene Expression
20%
Geographic Region
20%
Combination Therapy
20%
Carbapenemases
20%
Old Drugs
20%
Antibiotic Resistance
20%
Clonal Spread
20%
Colistin
20%
Complex Interplay
20%
Susceptible Strain
20%
Therapy Strategy
20%
Carbapenems
20%
Antibiotic Agents
20%
Resistance Emergence
20%
Resistant Bacteria
20%
Cell-cell Interaction
20%
Multidrug-resistant Clones
20%
Resistance Genes
20%
Sulbactam
20%
Transfer Resistance
20%
Acinetobacter Baumannii (A. baumannii)
20%
Antibiotic Resistance Determinants
20%
New Antibiotics
20%
Area Strain
20%
Genetic Potential
20%
Resistance to Therapy
20%
Pseudomonas Aeruginosa Biofilm
20%
Pharmacokinetic Strategy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pseudomonas aeruginosa
100%
Acinetobacter Infection
100%
Infection
42%
Antimicrobial Resistance
28%
Hospital Infection
14%
Antibiotic Agent
14%
Antibiotics
14%
Combination Therapy
14%
Penicillinase
14%
Immunotherapy
14%
Carbapenem Derivative
14%
Colistimethate
14%
Carbapenemase
14%
Acinetobacter Baumannii
14%
Sulbactam
14%
Pharmacokinetics
14%
Antimicrobial Agent
14%
Immunology and Microbiology
Pseudomonas aeruginosa
100%
Acinetobacter Baumannii
100%
Antimicrobial Resistance
28%
Cell Interaction
14%
Biofilm
14%
Gene Expression
14%
Pharmacokinetics
14%
Immunotherapy
14%
Colistin
14%
Antimicrobial Agent
14%